ADC Therapeutics SA (ADCT) vs HUTCHMED (China) (HCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 12.0% versus a loss of 62.3%. Over five years, HCM leads with a -56.3% price change compared with -93.2% for ADCT. HUTCHMED (China) is the larger company by market cap ($2.45 billion vs $220.9 million), about 11.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | HCM |
|---|---|---|
| Share price | $1.73 | $14.10 |
| Market cap | $220.87M | $2.45B |
| 1-day change | +8.81% | +3.15% |
| YTD return | -50.99% | +5.78% |
| 1-year return | -62.31% | -11.99% |
| 5-year return | -93.21% | -56.35% |
| P/E ratio (TTM) | — | 141.00 |
| Forward P/E | — | 54.40 |
| EPS (TTM) | $-0.60 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $548.51M |
| Revenue growth (YoY) | — | -12.96% |
| Net income (latest FY) | — | $456.91M |
| Gross margin | — | 38.68% |
| Operating margin | — | -7.14% |
| Net margin | — | 83.30% |
| 52-week high | $4.98 | $16.33 |
| 52-week low | $0.78 | $9.77 |
| Distance from 52-week high | -65.26% | -13.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +92.49% | +56.10% |
| Average volume | 1.43M | 68.02K |
| Shares outstanding | 127.67M | 173.81M |
| Employees | 188 | 1,790 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUTCHMED (China) is about 11.1 times larger than ADC Therapeutics SA by market value ($2.45B vs $220.87M).
- HCM has outperformed ADCT by 50.3 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Healthcare · Drug Manufacturers - Specialty & Generic · 188 employees
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,790 employees
ADCT vs HCM FAQ
Which is bigger, ADC Therapeutics SA or HUTCHMED (China)?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.45B compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or HCM?
HCM returned -11.99% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and HUTCHMED (China) in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.